Alexandria, Va., July 29, 2021 — Following the FDA’s approval of the first interchangeable biosimilar insulin product, AMCP released the below statement:
Statement from Susan Cantrell, AMCP chief executive officer:
"AMCP applauds the FDA’s decision to approve this product. This approval will allow pharmacists to substitute biosimilar insulin for the innovator insulin at the pharmacy counter for the first time. In this case, interchangeability means that more people will be able to access insulin products, leading to lives saved and lower health care costs for patients. More broadly, interchangeability and biosimilars will lead to large savings and more access to critical medicines for patients.
“Biosimilars are expected to deliver up to $100 billion in savings to the U.S. health care system in the next five years, and are essential to millions of Americans across the country who live with chronic conditions. We’re excited by this approval at the FDA and look forward to continuing to work across the entire drug supply chain to ensure more patients have access to the medications they need at a cost they can afford.”
About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
